Testimonials

“CRISPR has become a powerful discovery tool, and the field is now at an inflection point. The promise of translating insights into clinical applications to treat a myriad of serious diseases, including cancer and genetic disorders, is within reach. With Synthego’s full stack of proprietary platforms, clinical-grade manufacturing capabilities, and strong relationships in industry, academia and the investor community, we are well positioned to help our customers usher in this new era of genetic and cellular medicines, ultimately ensuring these therapies are accessible to all patients,” said Paul Dabrowski, co-founder and CEO of Synthego

Paul Dabrowski, co-founder and CEO of Synthego

“Everyone is thinking about the therapeutic application of CRISPR, but sometimes we forget that the first thing that CRISPR does is searching.”  ~ Kiana Aran, Assistant Professor, Keck Graduate Institute

Kiana Aran,

“The introduction of gene editing and CRISPR-based approaches in the clinic will likely begin with T-cell therapies because of the relative ease of T-cell manipulation and transduction, combined with the relevance of T-cell therapies to a large number of disorders, including cancer and others.”  ~ Dr. Michel Sadelain, MD, Ph.D.

Dr. Michel Sadelain, MD, PHD,

“CRISPR-Cas9 is like molecular scissors, while base editors are like pencils...For some applications, scissors are the best tool for the job, while for other applications, such as fixing a single letter in DNA, a pencil is best.” ~ Dr. David Liu

Dr. David Liu,